

Book by 18th December 2009 to receive a £100 early bird discount

SMi presents their 12th annual conference...

Superbugs and Superdrugs

Overcoming Resistance

Wednesday 17th and Thursday 18th March 2010
Crowne Plaza St James Hotel, London

KEY SPEAKERS INCLUDE:

Dr Katsura Hata
Senior Researcher
Eisai Product Creation Systems

Dr Alan Johnson
Clinical Scientist
Health Protection Agency

Dr Graham Dixon
Senior Vice President Drug Discovery
Galapagos NV

Dr Frank Koehn
Director – Biosynthetic and Discovery Analytical Chemistry
Pfizer

Professor Peter Hawkey
Professor of Public Health Bacteriology
University of Birmingham and Health Protection Agency

Dr Brian Noonan
Director of Bioscience, Infection Discovery
AstraZeneca

KEY TOPICS INCLUDE:

- Government support for the development of new antimicrobials
- Overcoming resistance
- Tackling antibiotic resistance in gram negative bacteria
- Establishing alliances with large pharma to develop new antibacterials
- New approaches to fungal and protozoal infections
- Discovering novel classes of antibacterial agents

SMi's 12th Annual Conference will bring you up to date with new and emerging products in the antimicrobials market. With a particular focus on antibacterials and antifungals this conference will allow you to learn from and network with some of the leading individuals and organisations in this important area.

PLUS THREE INTERACTIVE HALF DAY WORKSHOPS

Crowne Plaza St James Hotel, London

A Global health as an investment opportunity

In association with: McKenna Long & Aldridge
Tuesday 16th March 2010, AM

B Preparing an R&D product for out-licensing and due diligence

In association with: David Scott
Tuesday 16th March 2010, PM

C Setting up Phase I, II, III clinical trials with antibiotics anti-infectives for small to medium sized companies

In association with: TranScrip Partners
Friday 19th March 2010, AM

OFFICIAL SUPPORTERS:

Anti-Infective
Drug News

Expert Reviews
Anti-infective Therapy
www.expertreviews.com

rapid.
microbiology

Anti-Infective Agents
In Medicinal Chemistry

www.smi-online.co.uk/2010superbugs.asp

Register online and receive full information on all of SMi's conferences

Alternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

Superbugs & Superdrugs

Day One | Wednesday 17th March 2010

www.smi-online.co.uk

8.30 Registration & Coffee

9.00 **Chairman's opening remarks**
Richard Bax, Senior Partner, **TranScrip Partners LLP**

CURRENT AND FUTURE ISSUES IN ANTIMICROBIALS

9.10 **Global update on emerging antibiotic resistant pathogens**

- What are the emerging threats
- How serious are they?
- Treatments available
- Timescales

Professor Peter Hawkey, Professor of Public Health Bacteriology, **University of Birmingham and Health Protection Agency**

9.50 **Government support for the development of new antimicrobials**

- Funding opportunities
- Supporting R&D
- Approaches for support of novel biotechnologies
- Leveraging data from more centralised health care systems to develop policy and regulation

Dr Jennifer Hanneschlager, Managing Director, Washington DC, **McKenna Long & Aldridge LLP**

10.30 Morning Coffee

11.00 **Infectious disease biomarkers**

- Biomarkers in TB
- T-cells
- Usage
- Next steps

Professor Ajit Lalvani, Chair of Infectious Diseases, National Heart & Lung Institute, **Imperial College London**

11.40 **The role of pharma SMEs in meeting the challenge for new antimicrobials**

- SME/biotechs – filling the big pharma gap
- Gaining support and finance for new antimicrobial product development

Dr Bill Love, Chief Executive, **Destiny Pharma**

12.20 Networking Lunch

1.40 **Antimicrobial pharmacodynamics and pharmacokinetics in practice**

- Assessing the activity of an antimicrobial
- Dosing and antimicrobial effect
- Indications of antimicrobial potency
- Post antibiotic effect

Professor Alasdair MacGowan, Professor of Clinical Microbiology & Antimicrobial Therapeutics, **University of Bristol/North Bristol NHS Trust**

UPDATE ON RESISTANCE

2.20 **Overcoming resistance**

- How can resistance be overcome
- The importance of surveillance and feedback of data
- Infection control
- Antibiotic stewardship

Dr Alan Johnson, Clinical Scientist, **Health Protection Agency**

3.00 **Multidrug resistance – *Acinetobacter baumannii***

- Multidrug resistance
- Reduced susceptibility to tigecycline
- Treatments
- Threat to the critically ill

Dr David Wareham, Clinical Senior Lecturer & Honorary Consultant, Centre for Infectious Disease, **Barts and The London School of Medicine and Dentistry**

3.40 Afternoon Tea

4.10 **Responding to the emerging global challenge of bacterial multidrug resistance**

- Current state and future directions of pharmaceutical antibacterial research
- Discovering new antibacterial agents in the 21st century
- Alternative therapeutic and preventive approaches for serious nosocomial infections

Dr John P. Mueller, Senior Director, Biology Lead, Antibacterials Research, **Pfizer Global Research and Development**

4.50 **Novel approaches to prevent side effects and emergence of bacterial resistance during antibiotic treatment**

- Emergence of resistance during antibiotic treatments: clinical data
- Possible strategies of prevention
- Products in development
- Development challenges /opportunities

Dr Jean de Gunzburg, Chief Scientific Officer, **Da Volterra**

5.30 **Chairman's closing remarks and close of day one**


Register online at www.smi-online.co.uk/2010superbugs.asp • Alternat

Who should attend:

All those responsible for research, medical microbiology, antimicrobial therapeutics, clinical development and business development, including:

- Chief Scientific Officers
- Senior Vice Presidents
- Chief Medical Officers
- Research Scientists
- Clinical Microbiologists
- R&D Project Managers
- Heads of Anti-Infectives Discovery

SMi Superbugs and Superdrugs past delegate breakdown:



Supported by



8.30 Re-registration & Coffee

9.00 **Chairman's opening remarks**

Professor Anthony Coates, Professor of Medical Microbiology,
St George's, University of London

DEVELOPMENTS IN ANTIBACTERIALS AND ANTIFUNGALS

9.10 **Tackling antibiotic resistance in gram-negative bacteria**

- Resistance mechanisms
- Strategies to tackle the antibiotic resistance
- Possible solutions
- Beta-lactams

Dr Laurenz Kellenberger, Chief Scientific Officer, **Basilea Pharmaceutica**

9.45 **Lantibiotics as leads for new antibacterials**

- Introduction to lantibiotics
- Structural modification by molecular biology and chemistry
- NVB302, a selective antibiotic for Clostridium difficile infection
- Lantibiotics for systemic infection

Dr Mike Dawson, Chief Scientific Officer, **Novacta**

10.20 Morning Coffee

10.50 **The path from biological activity to drug - Lytxar™ (LTX-109)**

- Cationic antimicrobial peptides - a much-talked-about source of novel drugs
- Building the next generation peptidomimetics
- LTX-109, a novel broad spectrum antimicrobial agent

Dr Anders Fugelli, Head of Business Development, **Lytx Biopharma**

11.25 **Strategic alliances with large pharma to develop new antibacterials**

- The alliance model
- Galapagos' alliance in anti-infectives
- Natural products as a source of anti-infectives
- Galapagos' natural product platform
- Challenges with natural product-based anti-infective programmes

Dr Graham Dixon, Senior Vice President Drug Discovery, **Galapagos NV**

12.00 **New approaches to fungal and protozoal infections**

- Ravuconazole as antifungal and antiprotozoal
- Discovery of new target for antifungal
- Pre-clinical efficacy of new antifungal

Dr Katsura Hata, Senior Researcher, **Eisai Product Creation Systems**

12.35 Networking Lunch

1.50 **Developing new echinocandins**

- Targets
- Spectrum of activity
- Toxicity
- Clinical efficacy

Dr John Northfield, Medical Advisor, **Astellas**

NOVEL APPROACHES

2.25 **Phage therapy for microbial resistance**

- Toxicity
- Safety and efficacy
- Preventative benefits
- Internal and topical application

Dr Nick Housby, Chief Operating Officer & Director, **Novolytics**

3.00 **Discovering novel classes of antibacterial agents - challenges and early successes**

- The need for novel classes
- The ongoing evolution of bacterial target validation
- Learnings from industry's approach to lead generation
- Progression towards the clinic

Dr Brian Noonan, Director of Bioscience, Infection Discovery, **AstraZeneca**

3.35 Afternoon Tea

4.05 **Antibiotic Peptides in dermatology**

- Antimicrobial peptides challenges and potential
- Peptide screening
- Target specificity and spectrum of activity
- Drug development in a virtual company
- DPK-060 an antimicrobial peptide in clinical development

Dr Jan Alenfall, Chief Executive Officer, **DermaGen**

4.40 **New antimicrobials from natural products: Opportunities and challenges**

- Landscape- Past and Present
- Targets, libraries and screening strategies
- Exploiting Unique Opportunities
- Overcoming Unique Challenges

Dr Frank Koehn, Director- Biosynthetic and Discovery Analytical Chemistry, **Pfizer**

5.15 **Chairman's closing remarks and close of conference**

Live fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711

ABOUT THE SMI PHARMACEUTICAL TEAM

SMi have been involved in the Pharmaceutical industry since 1993 and have developed a series of informative and niche events, covering the latest issues and developments surrounding the industry. Events bring together senior industry professionals and serving companies who have a focus on being at the forefront of developments in this area. SMi aim to generate informed and topical discussion through the medium of both Conferences and Executive Briefings. Our Pharmaceutical events are research-based and content driven with regular contact with major industry personnel and cover a wide range of industry sectors. For more information please visit www.smi-online.co.uk/pharma.asp

SPONSORSHIP AND EXHIBITION OPPORTUNITIES

SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company's marketing strategy. Should you wish to join the increasing number of companies benefitting from sponsoring our conferences please call: Alia Malick on +44 (0)20 7827 6168 or email: amalick@smi-online.co.uk

Want to know how you can get involved? Interested in promoting your pharmaceutical services to this market? Contact Margaret Mugema, SMi Marketing on +44 (0) 20 7827 6072 or email: mmugema@smi-online.co.uk

HALF DAY PRE-CONFERENCE WORKSHOP A

Tuesday 16th March 2010
8.30am – 1pm
Crowne Plaza St James Hotel, London

In association with:

McKenna Long
& Aldridge
Attorneys at Law

Global health as an investment opportunity

This workshop will address the growing business of global health. Groups such as the Bill and Melinda Gates Foundation, BioVentures for Global Health, the Novartis Vaccines Institute for Global Health, Intercell, the Wellcome Trust, and Merck have all made strategic investments in the development of vaccines and therapeutics against infectious disease targets. However, the question still remains whether there will be the commercial or political appetite to commercialise products which have low margin, even if the target populations range in the billions. Speakers for this workshop will discuss the financing, development, and commercialization strategies, opportunities, and hurdles experienced working in this space.

Key reasons to attend:

- Gain an understanding of the global health space
- Discover market opportunities
- Learn from some leading figures in the area

8.30 Registration & Coffee

9.00 Welcome and introductions

9.15 Market incentives and opportunities

- How to get involved in the global health space
- Identification of needs
- Awareness of financial incentives
- Political/regulatory support to access new markets

10.45 Morning Coffee

11.15 Commercialisation strategies and disease indications

- Market opportunities for global health products
- Gaining global access
- Leveraging developed world markets/tiered pricing systems
- Sustaining executive/investor support

1.00 Wrap-up and close of workshop



About the workshop leaders:

Jennifer Hanneschlager, Ph.D., focuses on biodefense and public health preparedness. Specific areas of interest include emerging infectious diseases, advanced purchase agreements and global health markets, the Select Agent and Toxins regulations, and dual-use technologies.

Dr. Hanneschlager has more than 12 years of research experience with companies, universities and non-governmental organizations in London, Peru, Trinidad, Venezuela, and the United States. Most recently, she was a senior researcher with Thomson Medstat, a national health care intelligence and research company. While there, she was involved in the implementation and evaluation of epidemiological studies. Dr. Hanneschlager has extensive experience working in the areas of infectious disease control and policy, vector/virus interactions and viral transmission patterns.

HALF DAY PRE-CONFERENCE WORKSHOP B

Tuesday 16th March 2010
1.30pm – 5pm
Crowne Plaza St James Hotel, London

In association with:

David Scott
Licensing & Business Development Consultant

Preparing an R&D product for out-licensing and due diligence

This workshop will deal with the practical issues involved in out-licensing a research-based product. Delegates will learn how to set up an activity plan and a licensing team, how to prepare the critical product dossiers and presentations, and how to identify potential target partners. The workshop will examine how the evaluation process is conducted, including setting up confidentiality or Materials Transfer Agreements, and will discuss those elements of the package that are of particular importance for the licensing of anti-infective products.

Key reasons to attend:

- Gain an understanding into the intricacies of outsourcing a research based product
- Discover insights into how the evaluation process is conducted
- Discuss key issues influencing potential partners for anti-infectives

1.30 An overview of the licensing process

- Strategy
- Activity plan
- Assembling the team

4:00 Product evaluation and due diligence

- CDAs and MTAs
- Evaluation – a four step process
- Preparing answers to key questions

2:00 Preparing the marketing material

- Confidential dossier
- Non-confidential brochure
- Presentation
- Setting up a due diligence room
- Identifying target companies

4:45 Discussion on what are the key issues influencing potential partners for anti-infectives

5.00 Close of workshop

3:30 Afternoon Tea



About the workshop host

David Scott is a freelance licensing and business development consultant and a Certified Licensing Professional. With more than 25 years' experience in the healthcare sector, David has spent the past 13 years as a consultant and has successfully concluded many inward and outward licensing agreements, covering products and delivery systems for his clients. As a Director of Destiny Pharma, a UK company David also has direct experience working in the anti-infectives sector. He also provides licensing training and workshops for the pharmaceutical industry and is the author of the bestselling course, Scrip's Practical Guide to Pharmaceutical Licensing. For more information on David go to www.pharmaconsulting.co.uk

HALF DAY POST-CONFERENCE WORKSHOP C

Friday 19th March 2010

8.30am – 1pm

Crowne Plaza St James Hotel, London

In association with:



Setting up Phase I, II and III clinical trials with antibiotics and anti-infectives for small to medium sized companies

There are many issues surrounding the myriad tasks required to set up and efficiently manage clinical studies in the anti-infective area. Small to medium sized companies often possess minimal in-house resource and the skills required for this, often confusing, area of development. Critical issues for each phase of development including the preclinical phase will be discussed and tips provided on how to frame the important questions in order to obtain the right answers.

Who should attend:

Preclinical (e.g. microbiologists and research staff) and clinical development personnel including project /clinical trials managers and medical advisors.

Chief Scientific, Chief Medical Officers and CEO's of anti-infective companies. Scientists and licensing executives involved in due diligence activities for companies and venture capital companies.

Benefits of attending the workshop:

This workshop will enable small to medium-sized organisations to anticipate or identify:

- Organisational aspects within newly formed organisations or inter-company partnerships.
- Regulatory and developmental challenges associated with novel aspects of many anti infective agents.
- The importance of product labelling considerations from the earliest development phases.
- Critical learning points and the importance of advanced planning at each development stage.
- Typical problem areas during development and risks associated with "quick fixes"

About the workshop leaders:

Richard Bax is a Pharmaceutical Physician with over 32 years of industry experience, including working for Glaxo, Hoechst-Roussel, Lilly and ICI (now Astra Zeneca). He was VP at SmithKline Beecham from 1991-1999, working in London and Philadelphia, in charge of Global Anti-infective Clinical Development, resulting in over 15 successful NDAs /MAAs and launches including Famvir/penciclovir, Bactroban and Augmentin BD. In May 2007 he joined Viropharma as VP Clinical Director Europe and was involved in the set up of the EU company and the EU transplant maribivir phase 3 studies.



Flic Gabbay is a pharmaceutical physician with over 25 years of industry experience, including as Global Head of Anti-infectives, at Parke Davis in the US. She has worked for pharma and bio-tech companies in Europe and North America on a range of projects including monoclonals, transgenics, respiratory, anti-inflammatories, lipid lowering agents, anti-infectives and oncology. Flic is Non-executive Chairman of Phico Therapeutics, a novel antibiotic development company and has recently retired from the Board of Directors of Bioanalab after its successful acquisition.



PHARMACEUTICAL FORWARD PLANNER

JANUARY 2010

- 18/19 Paediatric Clinical Trials
- 18/19 KOL Nordics*
- 20/21 Pre-filled Syringes
- 27/28 Electronic Laboratory Notebooks

FEBRUARY 2010

- 01/02 Biomarkers Summit
- 03/04 Adaptive Designs in Clinical Drug Development
- 10/11 Parallel Trade
- 15/16 Stem Cells
- 22/23 Drug Design

MARCH 2010

- 10/11 Imaging in Oncology
- 15/16 Pharmacovigilance
- 17/18 Superbugs & Superdrugs
- 24/25 Accelerating Patient Recruitment in Clinical Trials

APRIL 2010

- 21/22 Asthma & COPD
- 21/22 Computer Systems Validation
- 26/27 High Throughput Screening
- 28/29 Controlled Release

MAY 2010

- 10/11 Generics, Supergenerics & Patient Strategies
- 17/18 Clinical Trial Logistics

JUNE 2010

- 07/08 Pain Therapeutics
- 14/15 KOL Europe*
- 17/18 Global Protein Summit
- 28/29 RNAi, siRNA & miRNA
- 28/29 Pharmaceutical Portfolio & Product Lifecycle Management

JULY 2010

- 05/06 Clinical Trials in Cancer
- 06/07 ADMET
- 12/13 In Vitro Diagnostics

*These conferences will take place in mainland Europe.

TRANSCRIPTION CD ROM

SMi are pleased to announce our Transcription CD ROM

WHAT DOES IT INCLUDE?

- The latest presentations from each expert speaker
- Carefully transcribed speaker documentation in PDF format
- Convenience of having information in text for ease of reference

COLLECTION CD ROM

Why not consider our collection CD ROM?

It will provide you with all the latest information as well as allow you to look back over the previous year's developments.

THIS COLLECTION INCLUDES:

- Superbugs & Superdrugs - Overcoming Resistance (2010)
- Superbugs & Superdrugs - A Focus on Antibacterial (2009)
- Superbugs & Superdrugs (2008)
- Superbugs & Superdrugs (2007)
- Superbugs & Superdrugs (2006)

Please Note: If would prefer not to receive this service you can opt out when making your booking. A fee of £100 will be deducted from your purchase.

Purchase this collection and save nearly £1500 in comparison to buying the individual CDROM's.

SUPERBUGS AND SUPERDRUGS

Conference: Wednesday 17th and Thursday 18th March 2010, Crowne Plaza St James Hotel, London Workshops: Tuesday 16th and Friday 19th March 2010, London

4 WAYS TO REGISTER

www.smi-online.co.uk/2010superbugs.asp

FAX your booking form to +44 (0) 870 9090 712

PHONE on +44 (0) 870 9090 711

POST your booking form to: Events Team, SMi Group Ltd, Great Guildford Business Square, 30 Great Guildford Street London, SE1 0HS, UK

Unique Reference Number	
Our Reference	LVU66

DELEGATE DETAILS

Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: _____ **Forename:** _____

Surname: _____

Job Title: _____

Department/Division: _____

Company/Organisation: _____

Email: _____

Address: _____

Town/City: _____

Post/Zip Code: _____ **Country:** _____

Direct Tel: _____ **Direct Fax:** _____

Mobile: _____

Switchboard: _____

Signature: _____ **Date:** _____

I agree to be bound by SMi's Terms and Conditions of Booking.

ACCOUNTS DEPT

Title: _____ **Forename:** _____

Surname: _____

Email: _____

Address (if different from above): _____

Town/City: _____

Post/Zip Code: _____ **Country:** _____

Direct Tel: _____ **Direct Fax:** _____

Terms and Conditions of Booking

Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested before entry to the event. CD ROMs will not be despatched until payment has been received.

Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not 'share' a place at an event. Please make separate bookings for each delegate.

Cancellation: If you wish to cancel your attendance at a Conference and/or Briefing and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regrettably cancellation after this time cannot be accepted. We will however provide the Conference documentation on CD ROM to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or CD ROM as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.

Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.

Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter.

EARLY BIRD DISCOUNT

Book by 18th December to receive a £100 Early Bird Discount

CONFERENCE PRICES

I would like to attend: (Please tick as appropriate)	Fee	+ VAT	Total
<input type="checkbox"/> Conference including transcription CD ROM only	£1399.00	+ VAT	£1608.85
<input type="checkbox"/> Conference and 1 Half-Day Workshop	£1898.00	+ VAT	£2182.70
<input type="checkbox"/> Conference and 2 Half-Day Workshops	£2397.00	+ VAT	£2756.55
<input type="checkbox"/> Conference and 3 Half-Day Workshops	£2896.00	+ VAT	£3330.40
<input type="checkbox"/> 3 Half-Day Workshops only	£1497.00	+ VAT	£1721.55
<input type="checkbox"/> 2 Half-Day Workshops only	£998.00	+ VAT	£1147.70
<input type="checkbox"/> 1 Half-Day Workshop only	£499.00	+ VAT	£573.85

Workshop(s) required A B C

Conference delegates not wishing to receive the Transcription CD of the Conference can deduct £115 (Inc VAT) from the pricing options listed above, which include the two day Conference, by ticking here

PROMOTIONAL LITERATURE DISTRIBUTION

Distribution of your company's promotional literature to all conference attendees £999.00 + VAT £1148.85

GROUP DISCOUNTS AVAILABLE

The conference fee includes refreshments, lunch, conference papers and CD ROM containing all of the presentations.

VENUE Crowne Plaza St James Hotel, Buckingham Gate, London SW1E 6AF

Please contact me to book my hotel

Alternatively call us on +44 (0) 870 9090 711, email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712

CD ROMS/DOCUMENTATION

I cannot attend but would like to purchase the following CD ROMs: (Shipped 10-14 days after the event)	Price	+VAT	Total
<input type="checkbox"/> Conference presentations on CD ROM (Slides only)	£499	+VAT	£573.85
<input type="checkbox"/> Conference Transcription CD ROM	£599	+VAT	£688.85
<input type="checkbox"/> Collection CD ROM, The last 5 year's CD package	£1099	+VAT	£1263.85

(Collection includes this year's transcription CD ROM and 4 non-transcribed events from previous years, offering a £1,500 saving)

PAYMENT

Payment must be made to **SMi Group Ltd**, and received before the event, by one of the following methods **quoting reference U66 and the delegate's name. Bookings within 7 days of event requires a credit card as guarantee. Please indicate method of payment:**

- UK BACS** Sort Code **300009**, Account **00936418**
- Wire Transfer** Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): **LOYDGB21013**, Account **00936418**
IBAN **GB48 LOYD 3000 0900 9364 18**
- Cheque** We can only accept Sterling cheques drawn on a UK bank.
- Credit Card** Visa MasterCard American Express

All credit card payments will be subject to standard credit card charges.

Card No:

Valid From / Expiry Date /

CVV Number 3 digit security on reverse of card, 4 digits for AMEX card

Cardholder's Name: _____

Signature: _____ **Date:** _____

I agree to be bound by SMi's Terms and Conditions of Booking.

Card Billing Address (If different from above): _____

VAT

VAT at 15% is charged on the attendance fees for all delegates. VAT is also charged on CD ROMs and Literature Distribution for all UK customers and for those EU customers not supplying a registration number for their own country here: _____